Part 1: Botanical and Chemical Profile
Erigeron breviscapus (Deng Zhan Xi Xin), a perennial herb native to Southwest China, yields the active compound breviscapine (scutellarin ≥90%).¹ This flavone glucuronide is extracted from aerial parts using:
- Ethanol/water solvent systems
- Macroporous resin purification
- Low-temperature crystallization²
The Chromatogram of Scutellarin17
Part 2: Research on Physiological Effects
In vitro and animal studies indicate potential bioactivities:
1. Cardiovascular System Support
- Modulates endothelial nitric oxide synthase (eNOS) activity³
- Supports healthy blood rheology in microcirculation models⁴
- Inhibits platelet aggregation ex vivo (IC50 = 28μM)⁵
2. Neurological Applications
- Crosses the blood-brain barrier in rodent studies⁶
- Attenuates glutamate-induced excitotoxicity in neurons⁷
- Enhances cerebral blood flow in ischemia models⁸
3. Antioxidant Mechanisms
- Scavenges superoxide radicals (ORAC: 18,500 μmol TE/g)⁹
- Upregulates endogenous SOD and GPx enzymes¹⁰
Part 3: Supplement Applications
Formulation Considerations
| Dosage Form | Bioavailability Enhancers | Stability Solutions |
|---|---|---|
| Tablets | Phospholipid complexes¹¹ | Oxygen-scavenging packaging |
| Injectables | Liposomal encapsulation¹² | Nitrogen headspace filling |
| Softgels | Medium-chain triglycerides | Light-resistant capsules |
Global Regulatory Status
China: Approved injectable (SFDA Z20026449)
EU: Novel Food application pending
USA: GRAS determination ongoing
Part 4: Market Analysis (2023-2030)
| Segment | CAGR | Key Drivers |
|---|---|---|
| Pharmaceuticals | 6.8% | Aging populations in Asia-Pacific¹³ |
| Nutraceuticals | 12.1% | Cognitive health demand¹⁴ |
| Cosmeceuticals | 8.7% | Anti-aging product innovation¹⁵ |
Supply Chain Dynamics
Raw Material: 80% from Yunnan Province (wild-cultivated)
Price Fluctuation: $220-380/kg (scutellarin 90%)
Quality Concerns: Adulteration with Erigeron annuus (HPLC differentiation required)¹⁶
Part 5: Technical Specifications
| Parameter | Specification | Test Method |
|---|---|---|
| Scutellarin | ≥90.0% | HPLC-UV (Chinese Pharmacopoeia) |
| Heavy Metals | <10ppm Pb, <0.5ppm Cd | ICP-MS |
| Residual Solvents | Ethanol <5000ppm | GC-FID |
| Microbial | TAMC <1000 CFU/g | USP <61> |
References
- Chinese Pharmacopoeia (2020) Vol I: 150-151.
- Zhang Y. et al. (2017) J Chromatogr B 1060: 291-297. DOI:10.1016/j.jchromb.2017.06.019
- Liu Z. et al. (2019) Front Pharmacol 10:403. DOI:10.3389/fphar.2019.00403
- Wang S. et al. (2015) Microvasc Res 101: 12-19.
- Zhang Z. et al. (2018) Thromb Res 164: 32-39.
- Li Y. et al. (2021) Pharmaceutics 13(7): 1070. DOI:10.3390/pharmaceutics13071070
- Shang Y. et al. (2020) Neurochem Res 45: 1008-1018.
- Liu P. et al. (2016) J Ethnopharmacol 190: 301-312.
- USDA ORAC Database (2023).
- Wang T. et al. (2019) Oxid Med Cell Longev 2019: 2745458.
- Chen J. et al. (2020) Drug Dev Ind Pharm 46(5): 792-799.
- Li X. et al. (2021) Int J Nanomedicine 16: 1995-2007.
- Grand View Research (2023) Cardiovascular Drugs Market Report.
- Nutrition Business Journal (2023) Brain Health Supplements.
- Kline & Co (2023) Cosmeceuticals: Global Market Analysis.
- Yao X. et al. (2022) J Pharm Biomed Anal 209: 114536.
- LU Jiang-yan et al. (2004) ANALYSIS AND TESTING TECHNOLOGY AND INSTRUMENTS Volume 10 Number 2. Article Number: 1006-3757 (2004) 02-0118-03